Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients

PloS One
Kathan MehtaRahul A Parikh

Abstract

Immunotherapy using high dose interleukin-2 (HD IL2) in patients with renal cell carcinoma (RCC) and melanoma is associated with severe toxicities. The association between annual hospital volume of HD IL2 and inpatient mortality is not well studied. In this study we aim to quantify the impact of annual hospital volume of HD IL2 on inpatient mortality using National Inpatient Sample (NIS) data. We did a cross-sectional study using NIS, one of the largest inpatient datasets in United States, from 2003 to 2011. Patients with melanoma and RCC receiving HD IL2 were identified by ICD9 procedure code 00.15. The primary outcome was inpatient mortality. Using Joinpoint regression, which detects change in trend of inpatient mortality with change in annual volume, the hospitals were classified in three volume categories (low: 1-40, medium: 41-120, high: >120). Multivariate logistic regression was used to identify predictors of inpatient mortality controlling for confounders. From 2003 to 2011, 29,532 patients with RCC or melanoma who received HD IL2 were identified, and 124 died during the hospitalization (0.4%). The hospitals with low, medium and high annual volume had significant difference in inpatient mortality (0.83%, 0.29% and 0.13%...Continue Reading

References

Jun 1, 1992·Journal of Clinical Epidemiology·R A DeyoM A Ciol
Nov 1, 1994·Journal of Clinical Epidemiology·M CharlsonJ Gold
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G FyfeA C Louie
Mar 23, 1994·JAMA : the Journal of the American Medical Association·S A RosenbergD E White
Dec 8, 1998·JAMA : the Journal of the American Medical Association·C B BeggM F Brennan
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M B AtkinsS A Rosenberg
May 15, 2009·Clinical and Experimental Dermatology·T FujimuraS Aiba
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Aug 30, 2011·The Journal of Thoracic and Cardiovascular Surgery·Christina M VassilevaStephen Hazelrigg
Jun 5, 2014·Statistics in Medicine·Hyune-Ju KimEric J Feuer
Sep 30, 2014·The New England Journal of Medicine·Georgina V LongKeith Flaherty
Sep 30, 2014·The New England Journal of Medicine·James LarkinAntoni Ribas
Nov 27, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David F McDermottMichael B Atkins
Sep 16, 2014·Journal for Immunotherapy of Cancer·Janice P DutcherMichael B Atkins

❮ Previous
Next ❯

Citations

Jan 18, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ethan A HalmDavid E Gerber
Feb 16, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ronald S GoDavid R Holmes
May 22, 2019·Journal of Oncology Practice·Michael J RaphaelChristopher M Booth
Apr 25, 2017·Journal of Hematology & Oncology·Kathan MehtaRahul A Parikh

❮ Previous
Next ❯

Methods Mentioned

BETA
pancreatectomy

Software Mentioned

SAS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.